歡迎光臨源葉生物,登錄 | 注冊(cè) |
當(dāng)前位置: 首頁 > 小分子抑制劑 > Apoptosis > GSK2801

瀏覽歷史

S81376

GSK2801

源葉(MedMol) 98%
  • 英文名:
  • GSK2801
  • 別名:
  • CAS號(hào):
  • 1619994-68-1
  • 分子式:
  • C20H21NO4S
  • 分子量:
  • 371.45
  • 核磁/質(zhì)譜:
品牌貨號(hào)產(chǎn)品規(guī)格價(jià)格(RMB) 庫存(上海) 北京 武漢 南京 數(shù)量計(jì)量單位 加入購物車...
源葉(MedMol) S81376-2mg 98% ¥255.00元 5 - - - EA 加入購物車
源葉(MedMol) S81376-5mg 98% ¥370.00元 5 - - - EA 加入購物車
源葉(MedMol) S81376-10mg 98% ¥495.00元 5 - - - EA 加入購物車
源葉(MedMol) S81376-25mg 98% ¥990.00元 6 - - - EA 加入購物車
源葉(MedMol) S81376-50mg 98% ¥1590.00元 預(yù)計(jì)交期:2-3天 - - - EA 加入購物車
源葉(MedMol) S81376-100mg 98% ¥2500.00元 預(yù)計(jì)交期:2-3天 - - - EA 加入購物車
大包裝詢價(jià)

提交您的電話號(hào)碼并同意《個(gè)人信息授權(quán)與保護(hù)申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻(xiàn)

質(zhì)檢證書(COA)

摩爾濃度計(jì)算器

相關(guān)產(chǎn)品

  • 提示:詳情請(qǐng)下載說明書。
  • 產(chǎn)品描述: GSK2801 is a potent, selective, orally active and cell active acetyl-lysine competitive BAZ2A and BAZ2B bromodomains inhibitor with Kd values of 136 nM and 257 nM, respectively. GSK2801 shows >50-fold selectivity for BAZ2A/B over BRD4
  • 靶點(diǎn): Kd: 136 nM (BAZ2A) and 257 nM (BAZ2B);Apoptosis;?EpigeneticReaderDomain
  • 體外研究:
    GSK2801 binds TAF1L(2) with an affinity KB of 0.31μM (KD: 3.2 μM) and a binding enthalpy change ΔH of ?8.6 kcal/mol. ITC experiments using the bromodomain of BRD9 results in the determination of an affinity KB of 0.826 μM (KD: 1.1 μM) and ΔH of ?9.8 kcal/mol. GSK2801 or RNAi knockdown of BAZ2A/B with JQ1 selectively displaced BRD2 at promoters/enhancers of ETS-regulated genes. In 2D cultures, enhances displacement of BRD2 from chromatin by combination drug treatment induced senescence. In spheroid cultures, combination treatment induces cleaved caspase-3 and cleaved PARP characteristic of apoptosis in tumor cells. Thus, GSK2801 blocks BRD2-driven transcription in combination with BET inhibitor and induces apoptosis of TNBC
  • 體內(nèi)研究:
    In order to determine the suitability of GSK2801 for in vivo experiments, pharmacokinetic parameters after intraperitoneal and oral dosing to male CD1 mice is measured. GSK2801 has reasonable in vivo exposure after oral dosing, modest clearance, and reasonable plasma stability
  • 參考文獻(xiàn):
    1. Chen P, et al. Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B. J Med Chem. 2016 Feb 25;59(4):1410-24. 2. Bevill SM, et al. GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer. Mol Cancer Res. 2019 Jul;17(7):1503-1518.
  • 溶解性: soluble  in  DMSO
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 2.692 ml 13.461 ml 26.922 ml
    5 mM 0.538 ml 2.692 ml 5.384 ml
    10 mM 0.269 ml 1.346 ml 2.692 ml
    50 mM 0.054 ml 0.269 ml 0.538 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號(hào):

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學(xué)研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。